June 16, 2009
NDA submitted for Loramyc, an antifungal for oropharyngeal candidiasisStrativa (a division of Par Pharmaceuticals) and BioAlliance Pharma announced the submission of a New Drug Application (NDA) to the FDA for Loramyc (miconazole Lauriad). If approved, Strativa could launch Loramyc in the second half of 2010.
Loramyc 50mg is a mucoadhesive buccal tablet for the treatment of oropharyngeal candidiasis.
For more information call (201) 802-4000 or visit www.strativapharma.com.